- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05012618
A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).
December 3, 2023 updated by: Chugai Pharmaceutical
A Phase 1 Open-label, Dose-escalation and Cohort Expansion Study of LUNA18 Monotherapy and Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors
This is a Phase 1 dose-escalation and cohort expansion study that will evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of LUNA18 when administered as a single agent or in combination with other anti-cancer drugs in patients with locally advanced or metastatic solid tumors.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
195
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Clinical trials information
- Phone Number: only use Email
- Email: clinical-trials@chugai-pharm.co.jp
Study Locations
-
-
Chiba
-
Kashiwa, Chiba, Japan, 277-8577
- Recruiting
- National Cancer Center Hospital East
-
-
Tokyo
-
Chuo-Ku, Tokyo, Japan, 104-0045
- Recruiting
- National Cancer Center Hospital
-
-
-
-
Michigan
-
Grand Rapids, Michigan, United States, 49546
- Recruiting
- South Texas Accelerated Research Therapeutics (START) Midwest
-
-
Nevada
-
Reno, Nevada, United States, 89502
- Recruiting
- Renown Regional Medical Center
-
-
Texas
-
Austin, Texas, United States, 78758
- Recruiting
- NEXT Oncology
-
Houston, Texas, United States, 77030
- Recruiting
- MD Anderson Cancer Center
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Recruiting
- Next Virginia
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- Recruiting
- University of Wisconsin - Carbone Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age >= 18 years at time of signing informed consent form
- ECOG performance status of 0 or 1
- Patients with a histologically or cytologically proven diagnosis of a locally advanced, recurrent, or metastatic incurable solid tumor for which standard therapy either does not exist or has proven ineffective or intolerable
- Patients with documented RAS alterations positive solid tumors
- Patients with measurable disease per RECIST v1.1
Exclusion Criteria:
- Significant cardiovascular disease, such as New York Heart Association (NYHA) cardiac disease (Class II or greater), unstable angina, or myocardial infarction within the previous 6 months or unstable arrhythmias within the previous 3 months
- Patients with primary central nervous system (CNS) malignancy, untreated CNS metastases requiring any anti-tumor treatment, or active CNS metastases
- Patients with current severe, uncontrolled systemic disease (including, but not limited to, clinically significant cardiovascular disease, pulmonary disease, or renal disease, ongoing or active infection)
- Patients with a history or complication of interstitial lung disease (ILD)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose escalation part (Part A)
Patients will receive LUNA18 capsule(s) at escalated doses
|
LUNA18 Capsule
|
Experimental: Biomarker part (Part B)
Patients will receive LUNA18 capsule(s) at doses where the tolerability is confirmed in Part A
|
LUNA18 Capsule
|
Experimental: Cohort expansion part (Part C)
Patients will receive LUNA18 capsule(s) at the recommended dose
|
LUNA18 Capsule
|
Experimental: Backfill part (Part AA)
Patients will receive LUNA18 capsule(s) at doses where the tolerability is confirmed in Part A
|
LUNA18 Capsule
|
Experimental: Dose finding part (Part D)
Patients will receive LUNA18 capsule(s) in combination with cetuximab at finding doses
|
LUNA18 Capsule
Cetuximab as a IV infusion
|
Experimental: Cohort expansion part (Part E)
Patients will receive LUNA18 capsule(s) in combination with cetuximab at the recommended dose
|
LUNA18 Capsule
Cetuximab as a IV infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phosphorylation level of ERK protein (pERK) in tumor tissues [Part B]
Time Frame: From screening until the time of clinical responses and/or the time of progressive disease (up to approximately 43 months), if feasible
|
Phosphorylation level of ERK protein (pERK) in tumor tissues biomarkers as applicable in tumor tissues
|
From screening until the time of clinical responses and/or the time of progressive disease (up to approximately 43 months), if feasible
|
Safety and tolerability of LUNA18 (Dose-limiting toxicities) when administered as a single agent [Part A] and in combination with other anti-cancer drugs [Part D]
Time Frame: From Cycle 0 Day 1 until Cycle 1 Day 28 (Cycle 0 is 6-9 days, and Cycle 1 is 28 days)
|
Incidence and nature of dose-limiting toxicities (DLTs)
|
From Cycle 0 Day 1 until Cycle 1 Day 28 (Cycle 0 is 6-9 days, and Cycle 1 is 28 days)
|
Safety and tolerability of LUNA18 (Adverse Events) [Part A, AA, B, C, D and E]
Time Frame: From Cycle 0 Day 1 (Cycle 0 is 6-9 days) until study completion or treatment discontinuation (up to approximately 43 months)
|
Incidence, nature and severity of adverse events, with severity determined per National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v5.0)
|
From Cycle 0 Day 1 (Cycle 0 is 6-9 days) until study completion or treatment discontinuation (up to approximately 43 months)
|
Plasma concentrations of LUNA18 when administered as a single agent [Part A, AA] and in combination with other anti-cancer drugs [Part D]
Time Frame: From Cycle 0 Day 1 (Cycle 0 is 6-9 days) until study completion or treatment discontinuation (up to approximately 43 months)
|
Plasma concentrations of LUNA18
|
From Cycle 0 Day 1 (Cycle 0 is 6-9 days) until study completion or treatment discontinuation (up to approximately 43 months)
|
Maximum plasma concentration (Cmax) of LUNA18 when administered as a single agent [Part A, AA] and in combination with other anti-cancer drugs [Part D]
Time Frame: From Cycle 0 Day 1 (Cycle 0 is 6-9 days) until study completion or treatment discontinuation (up to approximately 43 months)
|
Maximum plasma concentration (Cmax) of LUNA18
|
From Cycle 0 Day 1 (Cycle 0 is 6-9 days) until study completion or treatment discontinuation (up to approximately 43 months)
|
Time to reach maximum plasma drug concentration (Tmax) of LUNA18 when administered as a single agent [Part A, AA] and in combination with other anti-cancer drugs [Part D]
Time Frame: From Cycle 0 Day 1 (Cycle 0 is 6-9 days) until study completion or treatment discontinuation (up to approximately 43 months)
|
Time to reach maximum plasma drug concentration (Tmax) of LUNA18
|
From Cycle 0 Day 1 (Cycle 0 is 6-9 days) until study completion or treatment discontinuation (up to approximately 43 months)
|
Area under the concentration versus time curve (AUC) of LUNA18 when administered as a single agent [Part A, AA] and in combination with other anti-cancer drugs [Part D]
Time Frame: From Cycle 0 Day 1 (Cycle 0 is 6-9 days) until study completion or treatment discontinuation (up to approximately 43 months)
|
Area under the concentration versus time curve (AUC) of LUNA18
|
From Cycle 0 Day 1 (Cycle 0 is 6-9 days) until study completion or treatment discontinuation (up to approximately 43 months)
|
Preliminary anti-tumor activity of LUNA18 when administered as a single agent [Part B, C] and in combination with other anti-cancer drugs [Part E]
Time Frame: From screening until disease progression, study discontinuation, withdrawal or death, whichever occurs first (up to approximately 43 months)
|
Objective response, defined as a confirmed complete response (CR) or partial response (PR) as best overall response per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
|
From screening until disease progression, study discontinuation, withdrawal or death, whichever occurs first (up to approximately 43 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Preliminary anti-tumor activity of LUNA18 when administered as a single agent [Part A, Part AA] and in combination with other anti-cancer drugs [Part D]
Time Frame: From screening until disease progression, study discontinuation, withdrawal or death, whichever occurs first (up to approximately 43 months)
|
Objective response, defined as CR or PR as best overall response per RECIST v1.1
|
From screening until disease progression, study discontinuation, withdrawal or death, whichever occurs first (up to approximately 43 months)
|
Preliminary anti-tumor activity of LUNA18 [Part A, AA, B, C, D and E]
Time Frame: From screening until disease progression, study discontinuation, withdrawal or death, whichever occurs first (up to approximately 43 months)
|
Disease control, defined as CR, PR and stable disease (SD) per RECIST v1.1
|
From screening until disease progression, study discontinuation, withdrawal or death, whichever occurs first (up to approximately 43 months)
|
Preliminary anti-tumor activity of LUNA18 [Part A, AA, B, C, D and E]
Time Frame: From screening until disease progression, study discontinuation, withdrawal or death, whichever occurs first (up to approximately 43 months)
|
Duration of response (DoR), defined as the time from the first occurrence of a documented objective response to the time of the first documented disease progression per RECIST v1.1 or death from any cause, whichever occurs first
|
From screening until disease progression, study discontinuation, withdrawal or death, whichever occurs first (up to approximately 43 months)
|
Preliminary anti-tumor activity of LUNA18 [Part A, AA, B, C, D and E]
Time Frame: From screening until disease progression, study discontinuation, withdrawal or death, whichever occurs first (up to approximately 43 months)
|
Progression free survival (PFS), defined as the time from the first study treatment to the first occurrence of progression per RECIST v1.1 or death from any cause, whichever occurs first
|
From screening until disease progression, study discontinuation, withdrawal or death, whichever occurs first (up to approximately 43 months)
|
Anti-drug antibody to LUNA18[Part A, AA, B, C, D and E]
Time Frame: From Cycle 0 Day 1 (Cycle 0 is 6-9 days) until study completion or treatment discontinuation (up to approximately 43 months)
|
Incidence of anti-LUNA18 antibodies
|
From Cycle 0 Day 1 (Cycle 0 is 6-9 days) until study completion or treatment discontinuation (up to approximately 43 months)
|
Plasma concentrations of LUNA18 [Part B, C and E]
Time Frame: From Cycle 0 Day 1 (Cycle 0 is 6-9 days) until study completion or treatment discontinuation (up to approximately 43 months)
|
Plasma concentrations of LUNA18
|
From Cycle 0 Day 1 (Cycle 0 is 6-9 days) until study completion or treatment discontinuation (up to approximately 43 months)
|
Phosphorylation level of ERK protein (pERK) in tumor tissues [Part A, AA, C, D, E]
Time Frame: From screening until the time of clinical responses and/or the time of progressive disease (up to approximately 43 months), if feasible
|
Phosphorylation level of ERK protein (pERK) in tumor tissues biomarkers as applicable in tumor tissues
|
From screening until the time of clinical responses and/or the time of progressive disease (up to approximately 43 months), if feasible
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Sponsor Chugai Pharmaceutical Co. Ltd, clinical-trials@chugai-pharm.co.jp
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 8, 2021
Primary Completion (Estimated)
March 31, 2025
Study Completion (Estimated)
March 31, 2025
Study Registration Dates
First Submitted
August 3, 2021
First Submitted That Met QC Criteria
August 12, 2021
First Posted (Actual)
August 19, 2021
Study Record Updates
Last Update Posted (Actual)
December 8, 2023
Last Update Submitted That Met QC Criteria
December 3, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LUN101JG
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com).
For further details on Chugai's Data Sharing Policy and how to request access to related clinical study documents, see here (www.chugai-pharm.co.jp/english/profile/rd/ctds_request.html).
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Locally Advanced or Metastatic Solid Tumors
-
Hospices Civils de LyonUnknownMetastatic or Locally Advanced Solid TumorsFrance
-
University Medical Center GroningenActive, not recruiting
-
Merck KGaA, Darmstadt, GermanyCompletedLocally Advanced or Metastatic Solid TumorsHungary
-
Sichuan Baili Pharmaceutical Co., Ltd.Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.Not yet recruitingLocally Advanced or Metastatic Solid TumorsChina
-
Avistone Biotechnology Co., Ltd.Zhejiang Cancer Hospital; Henan Cancer Hospital; Hunan Cancer Hospital; Peking... and other collaboratorsRecruitingLocally Advanced or Metastatic Solid TumorsChina
-
TYK Medicines, IncRecruitingLocally Advanced or Metastatic Solid TumorsChina
-
Bio-Thera SolutionsRecruitingLocally Advanced or Metastatic Solid TumorsChina
-
Chugai PharmaceuticalRecruitingLocally Advanced or Metastatic Solid TumorsUnited States, Japan
-
Pierre Fabre MedicamentTerminatedLocally Advanced or Metastatic Solid TumorsFrance, Spain
-
OncoMed Pharmaceuticals, Inc.Celgene CorporationCompletedLocally Advanced or Metastatic Solid TumorsUnited States, United Kingdom